Anti-CTLA4 therapy using ipilimumab, has shown effective to improve overall survival in patients with melanoma and hepatocellular carcinoma, but is often used in combination with PD-1 inhibitors (62–65). The gene discussed is CTLA4; the disease is melanoma.